Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade

Stock Track11-11

Shares of Xeris Pharmaceuticals Inc. (XERS) plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.

Amsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.

The stock had been trading around $3.40 prior to the downgrade, but fell to a low of $3.13 in pre-market trading, representing a 7.78% decline. Investors appeared to react negatively to the analyst's revised stance, as downgrades can often signal potential concerns or challenges for a company's future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170797516?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170797516","market":"us","top_or_hot":-1,"title":"Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade","media":"Stock Track","content":"<p>Shares of Xeris Pharmaceuticals Inc. (XERS) plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.</p>\n\n<p>Amsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.</p>\n\n<p>The stock had been trading around $3.40 prior to the downgrade, but fell to a low of $3.13 in pre-market trading, representing a 7.78% decline. Investors appeared to react negatively to the analyst's revised stance, as downgrades can often signal potential concerns or challenges for a company's future performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Xeris Pharma Plunges in Pre-Market on Analyst Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-11 20:28 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Xeris Pharmaceuticals Inc. (XERS) plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.\nAmsellem lowered his ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"","article_id":"1170797516","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170797516","pubTimestamp":1731328096,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Xeris Pharmaceuticals Inc.  plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.Amsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.The stock had been trading around $3.4","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药"},"translate_title":"分析师下调评级后，Xeris Pharma股价盘前暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":1},"content_text":"Shares of Xeris Pharmaceuticals Inc. (XERS) plummeted over 7% in pre-market trading on Friday, November 11th, 2024, following a downgrade by Piper Sandler analyst David Amsellem.\nAmsellem lowered his rating on Xeris Biopharma from Overweight to Neutral, while maintaining his price target of $3 per share. The downgrade came after the company's third-quarter earnings report, though Amsellem did not provide specific details regarding the rationale behind his decision.\nThe stock had been trading around $3.40 prior to the downgrade, but fell to a low of $3.13 in pre-market trading, representing a 7.78% decline. Investors appeared to react negatively to the analyst's revised stance, as downgrades can often signal potential concerns or challenges for a company's future performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170797516"}